Patents by Inventor ELIZABETH ANNE JURICA

ELIZABETH ANNE JURICA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLIDINE GPR40 MODULATORS
    Publication number: 20200299267
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Application
    Filed: June 8, 2020
    Publication date: September 24, 2020
    Inventors: ELIZABETH ANNE JURICA, Zhenqiu Hong
  • Bridged bicyclic compounds as farnesoid X receptor modulators
    Patent number: 10730863
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 4, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Yoon, Rushith Kumar Anumula, Srinivas Cheruku, Yanting Huang, Elizabeth Anne Jurica, Wei Meng, Susheel Jethanand Nara, Rishikesh Narayan, Ramesh Kumar Sistla, Ximao Wu, Guohua Zhao
  • Pyrrolidine GPR40 modulators
    Patent number: 10717725
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 21, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Elizabeth Anne Jurica, Zhenqiu Hong
  • BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS
    Publication number: 20190127358
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 31, 2018
    Publication date: May 2, 2019
    Inventors: David S. Yoon, Rushith Kumar Anumula, Srinivas Cheruku, Yanting Huang, Elizabeth Anne Jurica, Wei Meng, Susheel Jethanand Nara, Rishikesh Narayan, Ramesh Kumar Sistla, Ximao Wu, Guohua Zhao
  • PYRROLIDINE GPR40 MODULATORS
    Publication number: 20190112293
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 18, 2019
    Inventors: ELIZABETH ANNE JURICA, Zhenqiu Hong